Abundant toxin-related genes in the genomes of beneficial symbionts from deep-sea hydrothermal vent mussels

  1. Lizbeth Sayavedra
  2. Manuel Kleiner
  3. Ruby Ponnudurai
  4. Silke Wetzel
  5. Eric Pelletier
  6. Valerie Barbe
  7. Nori Satoh
  8. Eiichi Shoguchi
  9. Dennis Fink
  10. Corinna Breusing
  11. Thorsten BH Reusch
  12. Philip Rosenstiel
  13. Markus B Schilhabel
  14. Dörte Becher
  15. Thomas Schweder
  16. Stephanie Markert
  17. Nicole Dubilier
  18. Jillian M Petersen  Is a corresponding author
  1. Max Planck Institute for Marine Microbiology, Germany
  2. Ernst-Moritz-Arndt-University, Germany
  3. Commissariat à l'énergie atomique et aux énergies alternatives, France
  4. Okinawa Institute of Science and Technology, Japan
  5. GEOMAR Helmholtz Centre for Ocean Research Kiel, Germany
  6. Institute of Clinical Molecular Biology, Germany
  7. Institute of Marine Biotechnology, Germany
  8. University of Vienna, Austria

Abstract

Bathymodiolus mussels live in symbiosis with intracellular sulfur-oxidizing (SOX) bacteria that provide them with nutrition. We sequenced the SOX symbiont genomes from two Bathymodiolus species. Comparison of these symbiont genomes with those of their closest relatives revealed that the symbionts have undergone genome rearrangements, and up to 35% of their genes may have been acquired by horizontal gene transfer. Many of the genes specific to the symbionts were homologs of virulence genes. We discovered an abundant and diverse array of genes similar to insecticidal toxins of nematode and aphid symbionts, and toxins of pathogens such as Yersinia and Vibrio. Transcriptomics and proteomics revealed that the SOX symbionts express the toxin-related genes (TRGs) in their hosts. We hypothesize that the symbionts use these TRGs in beneficial interactions with their host, including protection against parasites. This would explain why a mutualistic symbiont would contain such a remarkable 'arsenal' of TRGs.

Article and author information

Author details

  1. Lizbeth Sayavedra

    Max Planck Institute for Marine Microbiology, Bremen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Manuel Kleiner

    Max Planck Institute for Marine Microbiology, Bremen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  3. Ruby Ponnudurai

    Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Silke Wetzel

    Max Planck Institute for Marine Microbiology, Bremen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Eric Pelletier

    Genoscope - Centre National de Séquençage, Commissariat à l'énergie atomique et aux énergies alternatives, Evry, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Valerie Barbe

    Genoscope - Centre National de Séquençage, Commissariat à l'énergie atomique et aux énergies alternatives, Evry, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Nori Satoh

    Marine Genomics Unit, Okinawa Institute of Science and Technology, Onna, Japan
    Competing interests
    The authors declare that no competing interests exist.
  8. Eiichi Shoguchi

    Marine Genomics Unit, Okinawa Institute of Science and Technology, Onna, Japan
    Competing interests
    The authors declare that no competing interests exist.
  9. Dennis Fink

    Max Planck Institute for Marine Microbiology, Bremen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Corinna Breusing

    Evolutionary Ecology, GEOMAR Helmholtz Centre for Ocean Research Kiel, Kiel, Germany
    Competing interests
    The authors declare that no competing interests exist.
  11. Thorsten BH Reusch

    Evolutionary Ecology, GEOMAR Helmholtz Centre for Ocean Research Kiel, Kiel, Germany
    Competing interests
    The authors declare that no competing interests exist.
  12. Philip Rosenstiel

    Institute of Clinical Molecular Biology, Kiel, Germany
    Competing interests
    The authors declare that no competing interests exist.
  13. Markus B Schilhabel

    Institute of Clinical Molecular Biology, Kiel, Germany
    Competing interests
    The authors declare that no competing interests exist.
  14. Dörte Becher

    Institute of Marine Biotechnology, Greifswald, Germany
    Competing interests
    The authors declare that no competing interests exist.
  15. Thomas Schweder

    Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany
    Competing interests
    The authors declare that no competing interests exist.
  16. Stephanie Markert

    Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany
    Competing interests
    The authors declare that no competing interests exist.
  17. Nicole Dubilier

    Max Planck Institute for Marine Microbiology, Bremen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  18. Jillian M Petersen

    Department of Microbiology and Ecosystem Science, Division of Microbial Ecology, Research Network Chemistry Meets Microbiology, University of Vienna, Vienna, Austria
    For correspondence
    petersen@microbial-ecology.net
    Competing interests
    The authors declare that no competing interests exist.

Copyright

© 2015, Sayavedra et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,394
    views
  • 762
    downloads
  • 48
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Lizbeth Sayavedra
  2. Manuel Kleiner
  3. Ruby Ponnudurai
  4. Silke Wetzel
  5. Eric Pelletier
  6. Valerie Barbe
  7. Nori Satoh
  8. Eiichi Shoguchi
  9. Dennis Fink
  10. Corinna Breusing
  11. Thorsten BH Reusch
  12. Philip Rosenstiel
  13. Markus B Schilhabel
  14. Dörte Becher
  15. Thomas Schweder
  16. Stephanie Markert
  17. Nicole Dubilier
  18. Jillian M Petersen
(2015)
Abundant toxin-related genes in the genomes of beneficial symbionts from deep-sea hydrothermal vent mussels
eLife 4:e07966.
https://doi.org/10.7554/eLife.07966

Share this article

https://doi.org/10.7554/eLife.07966

Further reading

    1. Genetics and Genomics
    Yi Li, Long Gong ... Shangbang Gao
    Research Article

    Resistance to anthelmintics, particularly the macrocyclic lactone ivermectin (IVM), presents a substantial global challenge for parasite control. We found that the functional loss of an evolutionarily conserved E3 ubiquitin ligase, UBR-1, leads to IVM resistance in Caenorhabditis elegans. Multiple IVM-inhibiting activities, including viability, body size, pharyngeal pumping, and locomotion, were significantly ameliorated in various ubr-1 mutants. Interestingly, exogenous application of glutamate induces IVM resistance in wild-type animals. The sensitivity of all IVM-affected phenotypes of ubr-1 is restored by eliminating proteins associated with glutamate metabolism or signaling: GOT-1, a transaminase that converts aspartate to glutamate, and EAT-4, a vesicular glutamate transporter. We demonstrated that IVM-targeted GluCls (glutamate-gated chloride channels) are downregulated and that the IVM-mediated inhibition of serotonin-activated pharynx Ca2+ activity is diminished in ubr-1. Additionally, enhancing glutamate uptake in ubr-1 mutants through ceftriaxone completely restored their IVM sensitivity. Therefore, UBR-1 deficiency-mediated aberrant glutamate signaling leads to ivermectin resistance in C. elegans.

    1. Genetics and Genomics
    Minsoo Noh, Xiangguo Che ... Sihoon Lee
    Research Article

    Osteoporosis, characterized by reduced bone density and strength, increases fracture risk, pain, and limits mobility. Established therapies of parathyroid hormone (PTH) analogs effectively promote bone formation and reduce fractures in severe osteoporosis, but their use is limited by potential adverse effects. In the pursuit of safer osteoporosis treatments, we investigated R25CPTH, a PTH variant wherein the native arginine at position 25 is substituted by cysteine. These studies were prompted by our finding of high bone mineral density in a hypoparathyroidism patient with the R25C homozygous mutation, and we explored its effects on PTH type-1 receptor (PTH1R) signaling in cells and bone metabolism in mice. Our findings indicate that R25CPTH(1–84) forms dimers both intracellularly and extracellularly, and the synthetic dimeric peptide, R25CPTH(1–34), exhibits altered activity in PTH1R-mediated cyclic AMP (cAMP) response. Upon a single injection in mice, dimeric R25CPTH(1–34) induced acute calcemic and phosphaturic responses comparable to PTH(1–34). Furthermore, repeated daily injections increased calvarial bone thickness in intact mice and improved trabecular and cortical bone parameters in ovariectomized (OVX) mice, akin to PTH(1–34). The overall results reveal a capacity of a dimeric PTH peptide ligand to activate the PTH1R in vitro and in vivo as PTH, suggesting a potential path of therapeutic PTH analog development.